Medicines for dementia due to Alzheimer's disease and Parkinson's disease

Mattli R , Tzogiou C , Tomonaga Y , Sharakin M, Vinci L, Carlander M, Wirth B, Grobet C, Egli P, Nordström K, Gerber-Grote A, Puhan M, Wieser S
Record ID 32018002120
Project Status: Ongoing
Anticipated Publish Date: 2022
English language abstract: An English language summary is available
Publication Type: Full HTA
Country: Switzerland
MeSH Terms
  • Dementia
  • Alzheimer Disease
  • Parkinson Disease
  • Drug Therapy
  • Cholinesterase Inhibitors
  • Rivastigmine
  • Donepezil
  • Galantamine
  • Memantine
  • PROMs
  • efficacy
  • effectiveness
  • safety
  • costs
  • economics
  • cost-effectiveness
  • budget impact
  • legal
  • social
  • ethical
  • organisational
  • dementia
  • alzheimer disease
  • parkinson disease
Organisation Name: Swiss Federal Office of Public Health (FOPH)
Contact Address: Federal Office of Public Health, Schwarzenburgstrasse 157, CH-3003 Berne, Switzerland
Contact Name: Stephanie Vollenweider
Contact Email:
Copyright: Swiss Federal Office of Public Health
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.